Sorafenib in patients with refractory or recurrent multiple myeloma. [electronic resource]
Producer: 20140506Description: 197-200 p. digitalISSN:- 1099-1069
- Aged
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Combined Modality Therapy
- Drug Eruptions -- etiology
- Drug Resistance, Neoplasm
- Fatigue -- chemically induced
- Female
- Hematologic Diseases -- chemically induced
- Hematopoietic Stem Cell Transplantation
- Humans
- Interferon-alpha -- therapeutic use
- Lenalidomide
- Male
- Middle Aged
- Molecular Targeted Therapy
- Multiple Myeloma -- drug therapy
- Neoplasm Proteins -- antagonists & inhibitors
- Niacinamide -- adverse effects
- Pain -- chemically induced
- Phenylurea Compounds -- adverse effects
- Prospective Studies
- Protein Kinase Inhibitors -- adverse effects
- Recurrence
- Remission Induction
- Salvage Therapy
- Sorafenib
- Thalidomide -- analogs & derivatives
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.